论文部分内容阅读
为研制丹参酮Ⅱ_A纳米结构脂质载体(Tan Ⅱ_A-NLC),并进行体外透皮研究。该文采用高压均质技术制备Tan Ⅱ_ANLC,运用Box-Behnken设计-效应面法优化处方,并对其进行表征。采用Franze扩散池法评价Tan Ⅱ_A-NLC体外透皮性能。结果显示,以最优处方:脂药比为88、固液脂质比为2、稳定剂用量为1%,制得的Tan Ⅱ_A-NLC粒径为(182±14)nm,多分散指数(PDI)为0.190 6±0.024 5,Zeta电位(-27.8±5.4)m V,包封率(EE)为86.44%±9.26%,载药量(DL)为0.98%±0.18%;体外透皮吸收实验结果显示Tan Ⅱ_A-NLC的24 h药物累积透皮量低于溶液,但其在表皮中的滞留量是溶液的3.18倍。TanⅡ_A-NLC可有效提高Tan Ⅱ_A在表皮层的滞留量,具有广阔的应用前景。
For the development of tanshinone Ⅱ_A nanostructured lipid carrier (Tan Ⅱ_A-NLC), and in vitro transdermal study. In this paper, Tan Ⅱ_ANLC was prepared by high pressure homogenization technique. The formulation was optimized by Box-Behnken design-response surface method and characterized. The Franz diffusion cell method was used to evaluate the transdermal performance of Tan Ⅱ_A-NLC in vitro. The results showed that the particle size of TanⅡ_A-NLC was (182 ± 14) nm with polydispersity of 88, lipid-lipid ratio of 2 and stabilizer content of 1%. The polydispersity index PDI was 0.190 6 ± 0.024 5, Zeta potential was -27.8 ± 5.4 mV, encapsulation efficiency was 86.44% ± 9.26% and DL was 0.98% ± 0.18%. In vitro transdermal absorption The experimental results showed that the cumulative transdermal volume of Tan Ⅱ_A-NLC for 24 h was lower than that of the solution, but its retention in the epidermis was 3.18 times that of the solution. Tan Ⅱ_A-NLC can effectively increase the retention of Tan Ⅱ_A in the epidermis, which has broad application prospects.